Corcept Therapeutics Incorporatedbased In Menlo Parkcaliforniais A Biopharmaceutical Company Founded In 1998The Company Focuses On Discoveringdevelopingand Commercializing Therapies That Target Cortisol Modulation To Address Severe Medical Conditionsparticularly In Rare Endocrineoncologicand Metabolic Disordersled By Ceo Joseph Kbelanoffm D And Co Founder Alan Fschatzbergcorcept Aims To Improve Patient Outcomes Through Innovative Treatments Corcept S Flagship Product Is Korlyma Mifepristone An Fda Approved Medication For Managing Hyperglycemia In Adults With Endogenous Cushingae S Syndromethe Company Also Has A Diverse Pipelineincluding Relacorilantwhich Is In Late Stage Trials For Cushingae S Syndrome And Various Solid Tumorsand Miricorilantwhich Is Being Studied For Nonalcoholic Steatohepatitisnashand Weight Gain Related To Antipsychotic Medicationscorcept Is Dedicated To Advancing Cortisol Modulation Therapies And Addressing Unmet Medical Needs Across Multiple Disease Areas
